Unicycive Therapeutics (UNCY) EBITDA (2020 - 2026)
Unicycive Therapeutics' (UNCY) quarterly EBITDA came in at -$8.4 million in Q1 2026, down 5.61% YoY from -$8.9 million in Q1 2025, and down 16.79% on a QoQ basis from -$7.2 million in Q4 2025.
Unicycive Therapeutics (UNCY) EBITDA (2020 - 2026) Analysis & Trends
Unicycive Therapeutics (UNCY) has 7 years of EBITDA data on file, last reported at -$8.4 million in Q1 2026.
- Quarterly EBITDA fell 5.61% year-over-year to -$8.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$30.0 million (up 3.03% YoY) and the FY2025 annual result came in at -$29.5 million, up 8.1% from the prior year.
- EBITDA declined to -$8.4 million in Q1 2026, from -$7.2 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of -$3.5 million in Q1 2022 to a low of -$9.3 million in Q4 2024.
- A 5-year average of -$6.4 million and a median of -$6.3 million in 2023 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2022 — EBITDA tumbled 383.86% — and 2025, when it grew 22.0%.
- Tracing UNCY's EBITDA over 5 years: stood at -$5.3 million in 2022, then declined by 18.55% to -$6.3 million in 2023, then sank by 46.7% to -$9.3 million in 2024, then advanced by 22.0% to -$7.2 million in 2025, then decreased by 16.79% to -$8.4 million in 2026.
- The last three EBITDA figures came in at -$8.4 million (Q1 2026), -$7.2 million (Q4 2025), and -$7.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Unicycive Therapeutics | 147.24 Mn | 147.24 Mn | - | -10.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -10.14 Mn |
| Mar 31, 2026 | -8.44 Mn |
| Dec 31, 2025 | -7.22 Mn |
| Sep 30, 2025 | -7.34 Mn |
| Jun 30, 2025 | -6.96 Mn |
| Mar 31, 2025 | -7.99 Mn |
| Dec 31, 2024 | -9.26 Mn |
| Sep 30, 2024 | -6.25 Mn |
| Jun 30, 2024 | -7.40 Mn |
| Mar 31, 2024 | -9.20 Mn |
| Dec 31, 2023 | -6.31 Mn |
| Sep 30, 2023 | -5.94 Mn |
| Jun 30, 2023 | -4.32 Mn |
| Mar 31, 2023 | -4.20 Mn |
| Dec 31, 2022 | -5.33 Mn |
| Sep 30, 2022 | -5.55 Mn |
| Jun 30, 2022 | -3.64 Mn |
| Mar 31, 2022 | -3.54 Mn |
| Dec 31, 2021 | -2.75 Mn |
| Sep 30, 2021 | -4.72 Mn |